Portal de Periódicos da CAPES

Insulin like growth factor and risk of breast cancer

2013; Volume: 5; Issue: 5 Linguagem: Inglês

10.9790/5736-0555962

2278-5736

Abd ullah Athar Hasssan,

Metabolism, Diabetes, and Cancer

Background :-Breast cancer is responsible for the death of millions of women worldwide every year.It is widespread in the world and Iraq that become a genuine problem for public health.The etiology of the disease is unknown.Genetic and hormonal factors are involved in the development of breast cancer and progression of the disease.Insulin like growth factor-ӏ (IGF-ӏ) have been implicated as essential in controlling cellular differentiation and tissue regeneration, through mitogenic , anti-apoptotic and increases cell migration so IGF-ӏpromotetumorigenesis. Objective:-To evaluate the role of IGF-ӏ, insulin , estrogen and lipid profile in patients with breast cancer and their contribution to the pathogenesis of breast cancer.Subjects and Methods :-This study included 60 patients with primary breast cancer age range (29-70) years and 60 age matched healthy controls .The subjects were selected from patients attending the Clinic Medical City/Baghdad Teaching Hospital / Oncology unit .Insulin like growth factor-I, insulin and estrogen were measured by ELISA.Results:-Serum insulin like growth factor-I and insulin in breast cancer patients were significantly higher than healthy controls (p<0.01).The level of IGF-ӏ and estrogen are significantly higher in serum of premenopausal patients than the other studied groups( p<0.01).There were significantdifferences in cholesterol and low density lipoprotein (LDL) (p< 0.01), while there was no significant difference in the level of high density lipoprotein (HDL) between premenopausal patients and control (P>0.05),but there was a significant difference between postmenopausal patients and control group (P<0.01).. Conclusion :-Insulin like growth factor-ӏ and estrogen level increased in the breast cancer in premenopausal patients , these results suggested that levels of serum IGF-I and estrogen together can be used as a predictive markers for breast cancer in the premenopausal women.